UC research points to potential new treatment for pancreatic cancer
June 8, 2020
Researchers have discovered a new potential targeted treatment for pancreatic cancer. The next steps are clinical trials.
June 8, 2020
Researchers have discovered a new potential targeted treatment for pancreatic cancer. The next steps are clinical trials.
August 31, 2020
Shuchi Gulati, MD, is studying how treatments for patients with cancer and COVID-19 could cause other health complications, namely blood clots.
November 24, 2020
University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don’t.
May 23, 2022
The University of Cincinnati's Dr. Jennifer O’Toole is co-editor of the book “Women in Pediatrics: The Past, Present and Future.”
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
December 8, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology Annual Meeting, held Dec. 9-12 in San Diego, California.
November 7, 2023
The University of Cincinnati Cancer Center’s Vladimir Bogdanov found a new drug developed in his lab was effective at preventing pancreatic cancer growth and spread when combined with chemotherapy in lab tests.
February 15, 2024
The University of Cincinnati Cancer Center announced it is opening the Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, this summer.
February 20, 2024
The University of Cincinnati Cancer Center is the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
April 4, 2024
Clinical research conducted at the University of Cincinnati College of Medicine and UC Health played a role in the U.S. Food and Drug Administration's March 26 approval of WINREVAIR™ (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH) in adults.